SMS Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 13 Feb 2025
Result Summary
- SMS Pharmaceuticals Ltd reported a 11.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 7.7%.
- Its expenses for the quarter were down by 14.3% QoQ and up 4.5% YoY.
- The net profit increased 29.4% QoQ and increased 58.9% YoY.
- The earnings per share (EPS) of SMS Pharmaceuticals Ltd stood at 2.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 175.48 | 198.05 | 162.97 | -11.4% | 7.7% |
Total Expenses | 153.04 | 178.51 | 146.44 | -14.3% | 4.5% |
Profit Before Tax | 22.44 | 19.54 | 16.53 | 14.8% | 35.8% |
Tax | 5.36 | 5.68 | 4.24 | -5.6% | 26.4% |
Profit After Tax | 18.24 | 14.10 | 11.48 | 29.4% | 58.9% |
Earnings Per Share | 2.10 | 1.70 | 1.40 | 23.5% | 50.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
SMS Pharmaceuticals Ltd is a well-established pharmaceutical company primarily engaged in the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and intermediates. The company operates within the pharmaceutical industry, which is known for its significant role in the development and production of drugs and medicinal products. As of the most recent updates, SMS Pharmaceuticals continues to focus on expanding its product portfolio and enhancing its manufacturing capabilities. Unfortunately, specific recent major developments regarding the company are not available from the provided data. However, the company is known for its commitment to high-quality standards and innovation in the pharmaceutical sector.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), SMS Pharmaceuticals Ltd reported a total income of ₹175.48 crores. This represents a 7.7% increase year-over-year (YoY) from ₹162.97 crores in Q3FY24. However, there was an 11.4% decrease quarter-over-quarter (QoQ) from ₹198.05 crores in Q2FY25. The YoY growth indicates an upward trend in revenue compared to the same quarter in the previous year, while the QoQ decline suggests a reduction in income compared to the previous quarter. The financial data highlights fluctuations in revenue performance within the annual cycle, reflecting various market and operational dynamics.
Profitability
The profitability of SMS Pharmaceuticals Ltd in Q3FY25 shows significant improvement compared to both the previous quarter and the same period last year. The company's profit before tax (PBT) increased to ₹22.44 crores, marking a 14.8% rise QoQ from ₹19.54 crores in Q2FY25 and a substantial 35.8% increase YoY from ₹16.53 crores in Q3FY24. The profit after tax (PAT) also saw considerable growth, reaching ₹18.24 crores, which is a 29.4% increase QoQ from ₹14.10 crores and a 58.9% rise YoY from ₹11.48 crores. These figures reflect a strong profitability performance, supported by effective cost management, as indicated by the reduction in total expenses.
Operating Metrics
Key operating metrics for SMS Pharmaceuticals Ltd include the earnings per share (EPS), which increased to ₹2.10 in Q3FY25. This reflects a 23.5% improvement QoQ from ₹1.70 in Q2FY25 and a 50.0% increase YoY from ₹1.40 in Q3FY24. The company's total expenses in Q3FY25 were reported at ₹153.04 crores, marking a 14.3% decrease QoQ from ₹178.51 crores and a 4.5% increase YoY from ₹146.44 crores. Additionally, the tax expenses were reduced by 5.6% QoQ to ₹5.36 crores from ₹5.68 crores in the previous quarter, while showing a 26.4% increase YoY from ₹4.24 crores. These operating metrics provide insight into the company's financial management and efficiency in its operations.
